Print（PDF/207KB） Oct. 31, 2025 Finances
Sumitomo Pharma Announces Variances Between Its Financial Forecasts and the Actual Results for the Half-Year Ended September 30, 2025, and Revisions to Its Financial Forecasts for the Year Ending March 31, 2026
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative
Director, President and CEO: Toru Kimura; Securities Code: 4506,
Prime Market of TSE) announced today that variance occurred between
its financial forecasts for the half-year ended September 30, 2025,
which were announced on July 31, 2025, and the financial results for
the period announced today.
The Company also announced that it has revised its financial
forecasts for the fiscal year ending March 31, 2026, which were
announced on May 13, 2025, in light of recent performance trends.
1. Variances Between Its Financial Forecasts and the Actual Results for the Half-Year Ended September 30, 2025 (April 1, 2025 to September 30, 2025)
Please scroll horizontally to view more information.
(Millions of yen)
| Revenue | Core operating profit | Operating profit | Net profit attributable to owners of the parent |
Basic earnings per share | |
|---|---|---|---|---|---|
| Previous Forecasts (A) | 207,000 | 70,000 | 69,000 | 56,000 | ¥140.96 |
| Revised Forecasts (B) | 227,122 | 96,084 | 96,157 | 98,860 | ¥248.84 |
| Variance in amount (B－A) | 20,122 | 26,084 | 27,157 | 42,860 | － |
| Variance in percent (%) | 9.7 | 37.3 | 39.4 | 76.5 | － |
|
[Reference] Same period a year ago (Half-year ended September 30, 2024) |
180,749 | (38) | (8,179) | (32,229) | ¥(81.12) |
2. Revisions to Its Financial Forecasts for the Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)
Please scroll horizontally to view more information.
(Millions of yen)
| Revenue | Core operating profit | Operating profit | Net profit attributable to owners of the parent |
Basic earnings per share | |
|---|---|---|---|---|---|
| Previous Forecasts (A) | 355,000 | 56,000 | 54,000 | 40,000 | ¥100.68 |
| Revised Forecasts (B) | 429,000 | 97,000 | 98,000 | 92,000 | ¥231.57 |
| Variance in amount (B－A) | 74,000 | 41,000 | 44,000 | 52,000 | － |
| Variance in percent (%) | 20.8 | 73.2 | 81.5 | 130.0 | － |
|
[Reference] Previous year (Year ended March 31, 2025) |
398,832 | 43,153 | 28,804 | 23,634 | ¥59.49 |
- Note:
- Core operating profit is calculated by deducting from operating profit any gains and losses resulting from nonrecurring factors, including changes in fair value of contingent consideration, impairment losses, and business structure improvement expenses.
3. Reasons for the variances and the revisions
(1) The half-year ended September 30, 2025
Revenue exceeded the previously announced forecast primarily due to
strong sales of ORGOVYX® (therapeutic agent for advanced prostate
cancer) in the North America segment. On the other hand, selling,
general and administrative expenses and R&D expenses were lower
than expected, resulting in some expenses likely being recorded in
the second half of the fiscal year.
Consequently, for the six-month period ended September 30, 2025,
revenue increased by 20.1 billion JPY to 227.1 billion JPY, core
operating profit increased by 26.1 billion JPY to 96.1 billion JPY,
and operating profit increased by 27.2 billion JPY to 96.2 billion
JPY from the previous forecasts.
Net profit attributable to owners of the parent increased by 42.9
billion JPY from the previous forecast to 98.9 billion JPY, due to
increased operating profit, improved financial income/costs
resulting from the weaker-than-expected Japanese yen, and the
recording of a gain on the reversal of deferred tax liabilities.
(2) The fiscal year ending March 31, 2026
Revenue has been revised upward by 74.0 billion JPY from the
previous forecast to 429.0 billion JPY, reflecting the expectation
of continued strong sales in North America.
Core operating profit has been revised upward by 41.0 billion
JPY from the previous forecast to 97.0 billion JPY, as the gains
from the divestiture of the Asian business are expected to exceed
initial forecast, while gross profit is expected to increase due to
revenue growth.
Operating profit has been revised upward by 44.0 billion JPY to 98.0
billion JPY from the previous forecast due to increased core
operating profit, and net profit attributable to owners of the
parent has been revised upward by 52.0 billion JPY to 92.0 billion
JPY, taking into account a decrease in tax expenses and other costs
in the first half of the fiscal year.
The full-year foreign exchange assumption (average exchange rate for
the period) remains unchanged from the previous forecast at 145.0
JPY against 1 USD.
- Disclaimer Regarding Forward-looking Statements
- The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.
Inquiries from the Press